Professional Documents
Culture Documents
Jurnal Analisis 1
Jurnal Analisis 1
Abstract
Background: Cardiotocography is almost ubiquitous in its use in intrapartum care. Although it has been
demonstrated that there is some benefit from continuous intrapartum fetal monitoring using cardiotocography,
there is also an increased risk of caesarean section which is accompanied by short-term and long-term risks to the
mother and child. There is considerable potential to reduce unnecessary operative delivery with up to a 60% false
positive diagnosis of fetal distress using cardiotocography alone. ST analysis of the fetal electrocardiogram is a
promising adjunct to cardiotocography alone, and permits detection of metabolic acidosis of the fetus, potentially
reducing false positive diagnosis of fetal distress.
Methods: This study will be a single-centre, parallel-group, randomised controlled trial, conducted over 3 years. The
primary hypothesis will be that the proportion of women with an emergency caesarean section on ST analysis will
not equal that for women on cardiotocography monitoring alone. Participants will be recruited at the Women’s
and Children’s Hospital, a high-risk specialty facility with approximately 5000 deliveries per annum. A total of 1818
women will be randomised to the treatment or conventional arm with an allocation ratio of 1:1, stratified by parity.
The primary outcome is emergency caesarean section (yes/no). Statistical analysis will follow standard methods for
randomised trials and will be performed on an intention-to-treat basis. Secondary maternal and neonatal outcomes
will also be analysed. Additional study outcomes include psychosocial outcomes, patient preferences and cost-
effectiveness.
(Continued on next page)
* Correspondence: chris.wilkinson@sa.gov.au
3
Women’s and Children’s Hospital, Adelaide, South Australia, Australia
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Turnbull et al. Trials (2019) 20:539 Page 2 of 10
This sample size would also provide power to detect have electronic fetal monitoring (3200 women per
clinically meaningful differences in the secondary out- year). The US study [14] reported a consent and ran-
comes of interest. domisation rate of 25.6%. Assuming a conservative
This is achievable at the study hospital. Of 5000 consent and randomisation rate of only 20% of the
women per year birthing at the Women’s and Chil- over 9600 women thus eligible over a 3-year period,
dren’s Hospital, 12% have elective caesarean sections 1920 women would be consented and randomised.
and do not labour, and approximately 8% are born pre- Given the 1818 consented and randomised women re-
term, leaving 80% of women to labour at term (4000 quired in our sample size calculation, this sample size
women per year). Of these women, approximately 80% should be achievable.
Turnbull et al. Trials (2019) 20:539 Page 5 of 10
Fig. 2 The schedule of enrolment, interventions and assessments. CTG cardiotocography, ICU intensive care unit, STan ST analysis
usual care without prejudice. Demographic and clinical Obstetrics and Gynaecology (RANZCOG) guidelines
baseline data will be collected by the research midwife at [28]). Once clinically appropriate and safe, the mem-
or soon after trial entry. Clinical observation will com- branes will be ruptured, a FSE will be applied and STan
mence at randomisation and will end 6 weeks postna- monitoring will commence.
tally. The last contact for most women will be at
approximately 7 weeks post delivery with the receipt of a Conventional arm (CTG only)
psychosocial questionnaire. A subset of women consent- A CTG machine (Philips or Neoventa) in the delivery room
ing to additional follow-up will be contacted for a face- will be activated. A belt with a tocodynometer will be ap-
to-face interview after the questionnaire has been plied to the woman’s waist. External monitoring of the fetal
returned and a sub-sample of consecutive women will heart rate will commence by a belt-mounted Doppler
also be asked to complete a second questionnaire at monitor around her waist or, if clinically indicated, a FSE
about 16 weeks post delivery to understand patient pref- will be applied to the fetal scalp and monitoring will com-
erences using a Discrete Choice Experiment (DCE) sur- mence according to the RANZCOG guidelines [28].
vey (see Fig. 2).
Data collection
Randomisation and blinding Maternal and neonatal data will be collected from retro-
Once consent is obtained and eligibility criteria are met, spective case-note review by the research midwife who is
participants will be randomised to either the treatment not involved in the primary provision of care. The treat-
group (CTG + STan) or the conventional group (CTG only). ment allocation cannot be concealed because the con-
Simple randomisation with stratification for parity will be tent of the notes will reveal the care received. An
implemented to produce a pre-determined schedule with an independent review of 20 records will be completed to
allocation ratio of 1:1, with treatment allocations accessed validate the quality and accuracy of data entry. Out-
by a telephone-based system provided by NHMRC Clinical comes and timepoints of data collection are detailed in
Trials Centre at the University of Sydney. Fig. 2. Prospectively collected data will also be obtained
in order to construct a CONSORT flow chart [29, 30].
Description of treatment arms
Continuous electronic fetal monitoring will be con- Primary outcome
ducted by midwives and obstetricians who have been The primary outcome is emergency caesarean section
trained in the use of CTG and STan monitoring (holding (yes/no).
Australian national Fetal Surveillance Education Pro-
gram (FSEP) CTG accreditation, as well as in-house, in- Secondary outcomes
stitutional accreditation for competency at STan use and Maternal secondary outcomes include the following:
interpretation). Within 6 weeks of birth, all labours and type of labour; indication for induction; type of fetal
deliveries will be reviewed by a multidisciplinary panel monitoring received; cardio-monitoring method; number
of experienced clinicians to assess adherence to elec- and classification of CTG abnormalities and clinician re-
tronic fetal monitoring (CTG and STan) protocols and sponses; number and type of ST events and clinician re-
procedures. Any evidence of protocol and STan guide- sponses; adherence to STAN guidelines; use of and
line violations will be fed back to the relevant providers result for scalp pH and/or lactate; use of oxytocin infu-
to optimise protocol adherence. sion and length of use; complications of labour; length
of labour; use of pharmacologic analgesia and non-
Treatment arm (CTG + STan) pharmacologic pain relief; mode of delivery; declared
A STan-capable monitor (Neoventa) will be connected reason if caesarean section and Robson classification;
to a tocodynometer on a belt applied to the woman’s trial of assisted vaginal delivery resulting in caesarean
waist. If her membranes have been ruptured, a FSE will section; postpartum antibiotic use, endometritis and ma-
be applied to the occiput of the fetal scalp, and STan ternal readmission; maternal ICU admission; maternal
monitoring will commence and be interpreted according death; and length of stay.
to the STAN guidelines [27]. If membranes are still in- Neonatal secondary outcomes include the following:
tact, they will be artificially ruptured when it is safe and intrapartum fetal death; birth weight; gender; intubation
clinically appropriate. A FSE will then be applied, and or external cardiac massage at delivery; arterial and venous
STan monitoring commenced. If it is not possible or cord gases (pH, lactate, base excess); APGAR score at 1, 5
clinically appropriate to rupture the membranes, moni- and 10 min; limb or clavicular fracture; neonatal death;
toring via a belt-mounted Doppler monitor will be com- seizure(s); BRAINZ monitoring; presence and grade of
menced (as per clinical necessity, using the guidelines of neonatal encephalopathy; requirement for cooling; proven
the Royal Australian and New Zealand College of infection; antibiotic usage; potential complication from
Turnbull et al. Trials (2019) 20:539 Page 7 of 10
use of fetal scalp electrode; scalp trauma; admission to hospital systems from all participants in the study, the
neonatal intensive care, special care or qualified on ward; incremental cost per emergency caesarean section
length of stay; jaundice requiring phototherapy; respira- avoided will be calculated.
tory distress; meconium aspiration syndrome; major con-
genital malformation; other major complications; and Statistical analysis
neonatal readmission. Analysis of the randomised controlled trial will be per-
formed by the Data, Design, Statistics and Research IT
Additional study outcomes Service of Adelaide Health Technology Assessment
All participants in the study are offered the opportunity to (AHTA), School of Public Health, The University of Adel-
participate in research observing psychosocial outcomes aide. Statistical analysis will follow standard methods for
of the monitoring they received, and a sub-sample of con- randomised trials and will be performed on an intention-
secutive participants will also be offered the opportunity to-treat basis, according to treatment allocation at ran-
to participate in research regarding preferences, utilising a domisation. All analyses will follow a pre-specified statis-
DCE survey. In consenting to participate in the rando- tical analysis plan. For dichotomous outcomes including
mised controlled trial, participants also agree to being sent the primary outcome of caesarean section (yes/no), pro-
questionnaires during the postnatal period. portions will be compared between treatment groups
Women are invited to complete a psychosocial ques- using the relative risk with 95% CI, obtained from a log bi-
tionnaire which they will receive approximately 7 weeks nomial regression analysis with adjustment for strata (de-
after delivery, with the exception of women with severe fined by parity) used in the randomisation. Further log
adverse outcomes (e.g. fetal or neonatal death). The binomial regression analyses (for sensitivity) will examine
questionnaire has been constructed using several mea- the effect of adjustment for parity, as well as pre-specified
sures to examine satisfaction with continuous electronic prognostic baseline variables and/or variables not bal-
fetal monitoring, birth satisfaction, general health, post- anced (by chance) at baseline, with results reported as the
natal depression and infant feeding practices. These relative risk with corresponding 95% CIs. Categorical out-
tools have robust psychometric properties and have been comes with more than two categories will be modelled
successfully applied in the maternity setting in past stud- with multinomial or ordinal logistic regression (or an ap-
ies. The tools include the EQ-5D [31], the General propriate generalised linear model alternative) with adjust-
Health Questionnaire [32], the Edinburgh Postnatal De- ment for parity. Proportions will be compared between
pression Scale (EPDS) [33], a measure of infant feeding treatment groups with relative risks and 95% CIs where
[34] and the Birth Satisfaction Scale—Revised (BSS-R) possible. Continuous outcomes will be compared using
[35]. Also included are demographic questions, a purpose- differences between mean values estimated from linear or
designed scale of monitoring satisfaction, trade-off ques- generalised linear regressions (depending on the nature of
tions and open-ended questions on positive and negative the data) adjusted for parity (with 95% CIs). Secondary
experiences. A subset of women who return the question- analyses will explore evidence for heterogeneity of effects
naire, and indicated they are interested in participating, will between the two parity strata using interaction tests and
be contacted regarding a face-to-face interview in relation subgroup analyses. All subgroup comparisons will be pre-
to their satisfaction and experience with the continuous specified and performed with appropriate tests of inter-
electronic fetal monitoring they received. action. Although this study will be underpowered to de-
Women may also be invited to participate in a patient termine equivalence of neonatal outcomes or maternal
preference survey using a DCE which will examine what secondary outcomes, the neonatal data will be able to be
trade-offs women are likely to make in order to obtain incorporated into meta-analyses including neonatal data
advantages such as reduced change of emergency caesar- from previous clinical trials (including the use of individ-
ean section. A three-stage approach, previously success- ual patient data).
fully applied [36], will be followed: existing data from a For the psychosocial survey, analysis of the data will
qualitative study [37] conducted during the pilot study be blinded to the specific treatment group, with simple
will be used to determine the key factors (attributes) in- indicators ‘A’ and ‘B’ provided by AHTA.
fluencing preference; a preliminary questionnaire will be For the DCE, analysis will begin using multinomial
developed and piloted, providing data to inform an effi- logit (MNL) models and mixed logit models; alternative
cient experimental design for the main survey; and the model specifications (e.g. latent class models) may also
final DCE questionnaire will be sent to women at ap- be used to explore preference heterogeneity. Models will
proximately 16 weeks postnatal. be evaluated for goodness of fit using the likelihood-ratio
Lastly, a cost-effectiveness study will be completed at χ2 statistic for the global test of zero model coefficients,
the end of the randomised controlled trial. Taking a hos- McFadden’s pseudo R2 and Akaike’s information criter-
pital perspective, and utilising cost data generated by ion (AIC). MNL and mixed logit model results will be
Turnbull et al. Trials (2019) 20:539 Page 8 of 10
evidence-based choices about care in labour. Given the CW is an associate professor and consultant maternal fetal medicine
ubiquitous application of CTG monitoring, we also an- subspecialist, Women’s and Children’s Hospital, Adelaide, South Australia.
12. Schuit E, Amer-Wahlin I, Ojala K, Vayssiere C, Westerhuis ME, Marsal K, et al. 34. Noel-Weiss J, Taljaard M, Kujawa-Myles S. Breastfeeding and lactation
Effectiveness of electronic fetal monitoring with additional ST analysis in research: exploring a tool to measure infant feeding patterns. Breastfeed
vertex singleton pregnancies at >36 weeks of gestation: an individual Lact Res: exploring a tool to measure infant feeding patterns. 2014;9(1):172.
participant data metaanalysis. Am J Obstet Gynecol. 2013;208(3):187 e1–e13. 35. Martin CR, Hollins Martin C, Redshaw M. The Birth Satisfaction
13. Chandraharan E, Wiberg N. Fetal scalp blood sampling during labor: an Scale—Revised Indicator (BSS-RI). (Report). BMC Pregnancy and Childbirth.
appraisal of the physiological basis and scientific evidence. Acta Obstet 2017;17(1):277.
Gynecol Scand. 2014;93(6):544–7. 36. Howard K, Gerard K, Adelson P, Bryce R, Wilkinson C, Turnbull D. Women’s
14. Belfort MA, Saade GR, Thom E, Blackwell SC, Reddy UM, Thorp JM Jr, et al. A preferences for inpatient and outpatient priming for labour induction: a
randomized trial of intrapartum fetal ECG ST-segment analysis. N Engl J discrete choice experiment. BMC Health Serv Res. 2014;14(1):330.
Med. 2015;373(7):632–41. 37. Bryson K, Wilkinson C, Kuah S, Matthews G, Turnbull D. A pilot exploratory
15. Amer-Wåhlin I, Kjellmer I, Maršál K, Olofsson P, Rosén KG. Swedish investigation on pregnant women's views regarding STan fetal monitoring
randomized controlled trial of cardiotocography only versus technology. BMC Pregnancy and Childbirth. 2017;17(1):446.
cardiotocography plus ST analysis of fetal electrocardiogram revisited: 38. Independent Hospital Pricing Authority. Australian hospital patient
analysis of data according to standard versus modified intention-to-treat costing standards—version 4.0. 2018. https://www.ihpa.gov.au/
principle. Acta Obstet Gynecol Scand. 2011;90(9):990. publications/australian-hospital-patient-costing-standards-version-40.
16. Ojala K, Vääräsmäki M, Mäkikallio K, Valkama M, Tekay A. A Accessed 2 Apr 2019.
comparison of intrapartum automated fetal electrocardiography and 39. Australian Government. Australian Refined Diagnosis Related Groups.
conventional cardiotocography—a randomised controlled study. BJOG. Ageing DoHa. 2009. https://www.aihw.gov.au/reports/hospitals/ar-drg-data-
2006;113(4):419–23. cubes/notes. Accessed 2 Apr 2019.
17. Westgate J, Harris M, Curnow JSH, Greene KR. Randomised trial of 40. AIHW. Australia’s mothers and babies 2016—in brief. Perinatal statistics
cardiotocography alone or with ST waveform analysis for intrapartum series no. 34. Cat. no. PER 97. Canberra: Australian Institute of Health and
monitoring. Lancet (London, England). 1992;340(8813):194–8. Welfare; 2018.
18. Westerhuis MEMH, Visser GHA, Moons KGM, van Beek E, Benders MJ, Bijvoet 41. Altaf S, Oppenheimer C, Shaw R, Waugh J, Dixon-Woods M. Practices and
SM, et al. Cardiotocography plus ST analysis of fetal electrocardiogram views on fetal heart monitoring: a structured observation and interview
compared with cardiotocography only for intrapartum monitoring: a study. BJOG. 2006;113(4):409–18.
randomized controlled trial. Obstet Gynecol. 2010;115(6):1173. 42. Mayes ME, Wilkinson C, Kuah S, Matthews G, Turnbull D. Change in practice:
19. Gucciardo L, Blavier F, Faron G. Intrapartum fetal ECG ST-segment analysis. a qualitative exploration of midwives’ and doctors’ views about the
N Engl J Med. 2015;373(25):2480–1. introduction of STan monitoring in an Australian hospital. BMC Health Serv
20. Clinical Information Services (CIS). Clinical Information Services (CIS) Res. 2018;18(1):119.
database. Adelaide: Women's and Children's Hospital; 2014.
21. Amer-Wahlin I, Kallen K, Herbst A, Rydhstroem H, Sundstrom AK, Marsal K. Publisher’s Note
Implementation of new medical techniques: experience from the Swedish Springer Nature remains neutral with regard to jurisdictional claims in
randomized controlled trial on fetal ECG during labor. J Matern Fetal published maps and institutional affiliations.
Neonatal Med: the official journal of the European Association of Perinatal
Medicine, the Federation of Asia and Oceania Perinatal Societies, the
International Society of Perinatal Obstet. 2005;18(2):93–100.
22. Norén H, Blad S, Carlsson A, Flisberg A, Gustavsson A, Lilja H, et al. STAN in
clinical practice—the outcome of 2 years of regular use in the city of
Gothenburg. Am J Obstet Gynecol. 2006;195(1):7–15.
23. Blix E, Brurberg KG, Reierth E, Reinar LM, Oian P. ST waveform analysis
versus cardiotocography alone for intrapartum fetal monitoring: a
systematic review and meta-analysis of randomized trials. Acta Obstet
Gynecol Scand. 2016;95(1):16–27.
24. Bhide A, Chandraharan E, Acharya G. Fetal monitoring in labor: implications
of evidence generated by new systematic review. Acta Obstet Gynecol
Scand. 2016;85:5–8.
25. Wilkinson C, Kuah S, Bryson K, Mayes M, Matthews G, Nik B, et al. A pilot
randomised trial of STan fetal monitoring compared with CTG monitoring
alone. J Paediatr Child Health. 2017;53(S2):107.
26. National Health and Medical Research Council. Australian Code for the
Responsible Conduct of Research. Canberra: Australian Government, ACT; 2007.
27. Amer-Wahlin I, Arulkumaran S, Hagberg H, Maršál K, Visser G. Fetal
electrocardiogram: ST waveform analysis in intrapartum surveillance. BJOG
Int J Obstet Gynaecol. 2007;114(10):1191–3.
28. Royal Australian and New Zealand College of Obstetrics and Gynaecology.
Intrapartum fetal surveillance clinical guideline - Third Edition. 2014. ISBN 13:
978-0-646-92056-6.
29. Keech A, Gabski V, Pike R. Interpreting and reporting clinical trials. A guide
to the CONSORT statement and the principles of randomised controlled
trials. Strawberry Hill: Australasian Medical Publishing Company, NSW,
Australia; 2007.
30. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the
CONSORT statement to randomized trials of nonpharmacologic treatment:
explanation and elaboration. Ann Intern Med. 2008;148(4):295.
31. EuroQol Group. EuroQol—a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16(3):199–208.
32. Goldberg D, Williams Paul, D.P.M. A user's guide to the General Health
Questionnaire, NFER-Nelson, Windsor, Berks. 1988.
33. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression.
Development of the 10-item Edinburgh Postnatal Depression Scale. Br J
Psychiatry: the journal of mental science. 1987;150:782.